Table 1.
Baseline characteristics
| Insulin therapy | Basal | Basal–bolus | Premix | |||
|---|---|---|---|---|---|---|
| Add‐on therapy | Liraglutide | Placebo | Liraglutide | Placebo | Liraglutide | Placebo |
| FAS (n) | 50 | 50 | 27 | 28 | 50 | 52 |
| Age (years) | 58.6 ± 11.5 | 60.1 ± 10.7 | 59.2 ± 11.8 | 57.2 ± 13.1 | 65.1 ± 9.0 | 60.9 ± 10.8 |
| Duration of diabetes (years) | 12.24 ± 7.07 | 11.83 ± 7.13 | 14.34 ± 7.08 | 17.19 ± 7.40 | 16.39 ± 10.86 | 16.08 ± 9.80 |
| Female (%) | 36.0 | 36.0 | 51.9 | 53.6 | 52.0 | 42.3 |
| Male (%) | 64.0 | 64.0 | 48.1 | 46.4 | 48.0 | 57.7 |
| Bodyweight (kg) | 67.6 ± 12.6 | 65.2 ± 12.5 | 70.0 ± 21.2 | 66.1 ± 13.5 | 66.5 ± 13.8 | 66.4 ± 13.5 |
| BMI (kg/m2) | 25.9 ± 3.8 | 24.7 ± 3.6 | 26.6 ± 6.5 | 26.1 ± 4.7 | 26.2 ± 4.8 | 25.1 ± 4.1 |
| FPG (mg/dL) | 144 ± 45 | 147 ± 39 | 174 ± 49 | 163 ± 49 | 152 ± 36 | 167 ± 47 |
| HbA1c (%) | 9.0 ± 0.9 | 9.0 ± 0.9 | 8.9 ± 0.9 | 8.6 ± 0.8 | 8.5 ± 1.0 | 8.8 ± 0.9 |
| C‐peptide (ng/mL) | 0.98 ± 0.68 | 0.98 ± 0.67 | 1.06 ± 0.86 | 0.94 ± 0.73 | 1.06 ± 0.60 | 1.14 ± 0.91 |
| Total daily insulin dose (units) | 23 ± 12 | 20 ± 11 | 41 ± 15 | 43 ± 21 | 29 ± 12 | 29 ± 14 |
BMI, body mass index; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin. Full analysis set (FAS) values are mean ± standard deviation unless otherwise indicated.